Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Azitra Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 3 distinct art units. This one-to-one ratio suggests that each of the 3 pending office actions involves a different technical focus within the pharmaceutical field. The presence of 3 distinct art units indicates that the company's innovations are being reviewed in several different specialized groups.
GANGLE, BRIAN J is the busiest examiner for the company, currently overseeing 1 pending office action. With 3 pending office actions total, the portfolio is divided equally between 3 distinct examiners. This decentralized distribution means that each pending office action is subject to a different examiner's review. The company must therefore navigate the distinct standards of 3 separate art units and 3 different examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
| MCKNIGHT, CIARA A | 1 | 61.5% | +40.3% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17089220 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF SKIN DISEASES AND DISORDERS WITH LEKTI | D' AMBROSIO, THEA | 9d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17089220 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF SKIN DISEASES AND DISORDERS WITH LEKTI | D' AMBROSIO, THEA | 9d overdue |
| 18735645 | THERAPEUTIC TREATMENT OF SKIN DISEASE WITH RECOMBINANT COMMENSAL SKIN MICROORGANISMS | GANGLE, BRIAN J | — |
| 18599588 | AUXOTROPHIC STRAINS OF STAPHYLOCOCCUS BACTERIUM | MCKNIGHT, CIARA A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1655 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18735645 | THERAPEUTIC TREATMENT OF SKIN DISEASE WITH RECOMBINANT COMMENSAL SKIN MICROORGANISMS | GANGLE, BRIAN J | 1645 | §112DP | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18599588 | AUXOTROPHIC STRAINS OF STAPHYLOCOCCUS BACTERIUM | MCKNIGHT, CIARA A | 1655 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 17089220 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF SKIN DISEASES AND DISORDERS WITH LEKTI | D' AMBROSIO, THEA | 1654 | §102§103 | Final Rejection | 9d overdue | Pending | Nov 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAzitra Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Brian J Gangle has the most, with 1 of Azitra Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
